CA2578852A1 - Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency - Google Patents
Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency Download PDFInfo
- Publication number
- CA2578852A1 CA2578852A1 CA002578852A CA2578852A CA2578852A1 CA 2578852 A1 CA2578852 A1 CA 2578852A1 CA 002578852 A CA002578852 A CA 002578852A CA 2578852 A CA2578852 A CA 2578852A CA 2578852 A1 CA2578852 A1 CA 2578852A1
- Authority
- CA
- Canada
- Prior art keywords
- isomer
- enyl
- chloro
- estrogen receptor
- receptor modulator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000333 selective estrogen receptor modulator Substances 0.000 title claims abstract description 61
- 229940095743 selective estrogen receptor modulator Drugs 0.000 title claims abstract description 40
- 206010002261 Androgen deficiency Diseases 0.000 title claims abstract description 29
- 238000011282 treatment Methods 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 11
- 230000002265 prevention Effects 0.000 title claims abstract description 11
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 239000002207 metabolite Substances 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 53
- NKZTZAQIKKGTDB-QPLCGJKRSA-N Fispemifene Chemical compound C1=CC(OCCOCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 NKZTZAQIKKGTDB-QPLCGJKRSA-N 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 27
- 229950004684 fispemifene Drugs 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 26
- -1 benzothiophene compound Chemical class 0.000 claims description 25
- 206010058359 Hypogonadism Diseases 0.000 claims description 16
- 230000003247 decreasing effect Effects 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- 230000001833 anti-estrogenic effect Effects 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 230000001076 estrogenic effect Effects 0.000 claims description 10
- 210000003205 muscle Anatomy 0.000 claims description 10
- 239000000328 estrogen antagonist Substances 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 201000003368 hypogonadotropic hypogonadism Diseases 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 206010059594 Secondary hypogonadism Diseases 0.000 claims description 7
- 230000003920 cognitive function Effects 0.000 claims description 7
- LUMKNAVTFCDUIE-VHXPQNKSSA-N ospemifene Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-VHXPQNKSSA-N 0.000 claims description 7
- 208000008589 Obesity Diseases 0.000 claims description 6
- KSZGVNZSUJHOJA-UHFFFAOYSA-N Zindoxifene Chemical compound CC=1C2=CC(OC(C)=O)=CC=C2N(CC)C=1C1=CC=C(OC(C)=O)C=C1 KSZGVNZSUJHOJA-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 229950006514 zindoxifene Drugs 0.000 claims description 6
- 230000037182 bone density Effects 0.000 claims description 5
- 201000000585 muscular atrophy Diseases 0.000 claims description 5
- 102000006771 Gonadotropins Human genes 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010067572 Oestrogenic effect Diseases 0.000 claims description 4
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical class CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 4
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 229960003969 ospemifene Drugs 0.000 claims description 4
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- JICOGKJOQXTAIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-3-methyl-1-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]indol-5-ol Chemical compound C=1C=C(OCCN2CCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 JICOGKJOQXTAIP-UHFFFAOYSA-N 0.000 claims description 3
- XENFGWFELBTJTG-CYYJNZCTSA-N 3-[(e)-4-chloro-1-[4-(2-imidazol-1-ylethoxy)phenyl]-2-phenylbut-1-enyl]phenol Chemical compound OC1=CC=CC(C(=C(/CCCl)C=2C=CC=CC=2)\C=2C=CC(OCCN3C=NC=C3)=CC=2)=C1 XENFGWFELBTJTG-CYYJNZCTSA-N 0.000 claims description 3
- 206010012374 Depressed mood Diseases 0.000 claims description 3
- 208000036119 Frailty Diseases 0.000 claims description 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 3
- 108010086677 Gonadotropins Proteins 0.000 claims description 3
- 208000018565 Hemochromatosis Diseases 0.000 claims description 3
- 206010021067 Hypopituitarism Diseases 0.000 claims description 3
- BVVFOLSZMQVDKV-KXQIQQEYSA-N ICI-164384 Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](CCCCCCCCCCC(=O)N(C)CCCC)CC3=CC(O)=CC=C3[C@H]21 BVVFOLSZMQVDKV-KXQIQQEYSA-N 0.000 claims description 3
- 201000007493 Kallmann syndrome Diseases 0.000 claims description 3
- 208000008972 Laurence-Moon syndrome Diseases 0.000 claims description 3
- 206010028289 Muscle atrophy Diseases 0.000 claims description 3
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 claims description 3
- 206010053142 Olfacto genital dysplasia Diseases 0.000 claims description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 3
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 208000007502 anemia Diseases 0.000 claims description 3
- 206010003549 asthenia Diseases 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 230000006870 function Effects 0.000 claims description 3
- 239000002622 gonadotropin Substances 0.000 claims description 3
- 208000031424 hyperprolactinemia Diseases 0.000 claims description 3
- 201000002733 hypogonadotropic hypogonadism 23 with or without anosmia Diseases 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 229950002366 nafoxidine Drugs 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 230000009758 senescence Effects 0.000 claims description 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N thianaphthalene Natural products C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 208000010392 Bone Fractures Diseases 0.000 claims description 2
- 206010007733 Catabolic state Diseases 0.000 claims description 2
- 208000017667 Chronic Disease Diseases 0.000 claims description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 208000028399 Critical Illness Diseases 0.000 claims description 2
- 208000002249 Diabetes Complications Diseases 0.000 claims description 2
- 206010012655 Diabetic complications Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 206010053759 Growth retardation Diseases 0.000 claims description 2
- 206010022998 Irritability Diseases 0.000 claims description 2
- 206010029216 Nervousness Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 150000001336 alkenes Chemical group 0.000 claims description 2
- 230000008468 bone growth Effects 0.000 claims description 2
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 claims description 2
- 230000001925 catabolic effect Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 238000002283 elective surgery Methods 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 230000008717 functional decline Effects 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 231100000001 growth retardation Toxicity 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 208000000509 infertility Diseases 0.000 claims description 2
- 230000036512 infertility Effects 0.000 claims description 2
- 231100000535 infertility Toxicity 0.000 claims description 2
- 230000007774 longterm Effects 0.000 claims description 2
- 201000006938 muscular dystrophy Diseases 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- 230000008439 repair process Effects 0.000 claims description 2
- 208000001076 sarcopenia Diseases 0.000 claims description 2
- 230000035882 stress Effects 0.000 claims description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 2
- 125000000383 tetramethylene group Chemical class [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- JTTIEHQAQHMYJD-QPLCGJKRSA-N 2-[3-[(z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-n,n-dimethylethanamine Chemical compound CN(C)CCOC1=CC=CC(C(=C(\CCCl)C=2C=CC=CC=2)\C=2C=CC=CC=2)=C1 JTTIEHQAQHMYJD-QPLCGJKRSA-N 0.000 claims 2
- VYYWCVMTGYXAQJ-VHXPQNKSSA-N 2-[3-[(z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]ethanol Chemical group OCCOC1=CC=CC(C(=C(\CCCl)C=2C=CC=CC=2)\C=2C=CC=CC=2)=C1 VYYWCVMTGYXAQJ-VHXPQNKSSA-N 0.000 claims 2
- XZYDRUBEVFWAQF-WCWDXBQESA-N 3-[(e)-4-chloro-1-[4-(2-hydroxyethoxy)phenyl]-2-phenylbut-1-enyl]phenol Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=C(O)C=CC=1)=C(\CCCl)C1=CC=CC=C1 XZYDRUBEVFWAQF-WCWDXBQESA-N 0.000 claims 2
- XENFGWFELBTJTG-RQZHXJHFSA-N 3-[(z)-4-chloro-1-[4-(2-imidazol-1-ylethoxy)phenyl]-2-phenylbut-1-enyl]phenol Chemical compound OC1=CC=CC(C(=C(\CCCl)C=2C=CC=CC=2)\C=2C=CC(OCCN3C=NC=C3)=CC=2)=C1 XENFGWFELBTJTG-RQZHXJHFSA-N 0.000 claims 2
- 208000037921 secondary disease Diseases 0.000 claims 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 122
- 229960003604 testosterone Drugs 0.000 description 61
- 210000002966 serum Anatomy 0.000 description 18
- 102000009151 Luteinizing Hormone Human genes 0.000 description 7
- 108010073521 Luteinizing Hormone Proteins 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 239000000262 estrogen Substances 0.000 description 7
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 6
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 6
- 229940040129 luteinizing hormone Drugs 0.000 description 6
- 206010052649 Primary hypogonadism Diseases 0.000 description 5
- 229940028334 follicle stimulating hormone Drugs 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000003098 androgen Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000001836 utereotrophic effect Effects 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 3
- 102100030758 Sex hormone-binding globulin Human genes 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 229940046836 anti-estrogen Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000000079 gynecomastia Diseases 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000007257 malfunction Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000037257 muscle growth Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960005026 toremifene Drugs 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 208000026817 47,XYY syndrome Diseases 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- RQQZRMSBCGQJCV-JYIAACDBSA-N ClCC/C(=C(C1=CC=CC=C1)/C1=CC=C(OCCOCCO)C=C1)/C1=CC=CC=C1.ClCC/C(=C(C1=CC=CC=C1)/C=1C=C(OCCO)C=CC1)/C1=CC=CC=C1 Chemical compound ClCC/C(=C(C1=CC=CC=C1)/C1=CC=C(OCCOCCO)C=C1)/C1=CC=CC=C1.ClCC/C(=C(C1=CC=CC=C1)/C=1C=C(OCCO)C=CC1)/C1=CC=CC=C1 RQQZRMSBCGQJCV-JYIAACDBSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010011498 Cryptorchism Diseases 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000028482 Hypothalamic disease Diseases 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- 208000017924 Klinefelter Syndrome Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 201000004462 Leydig Cell Tumor Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 206010029748 Noonan syndrome Diseases 0.000 description 1
- 208000014993 Pituitary disease Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010066833 Sertoli cell-only syndrome Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 206010043315 Testicular failure Diseases 0.000 description 1
- 208000022914 Testicular regression syndrome Diseases 0.000 description 1
- 206010056894 XYY syndrome Diseases 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 238000009165 androgen replacement therapy Methods 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 description 1
- 229950005529 arzoxifene Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 201000000160 cryptorchidism Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000002566 gonadal dysgenesis Diseases 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 208000017402 pituitary gland disease Diseases 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004999 sex organ Anatomy 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 150000003515 testosterones Chemical class 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 201000004822 varicocele Diseases 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
This invention relates to a use of a selective estrogen receptor modulator, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency or diseases and disorders caused by androgen deficiency in a male individual.
Description
USE OF A SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR THE MANUFACTURE
OF A PHARMACEUTICAL PREPARATION FOR USE IN A METHOD FOR THE TREATMENT
OR PREVENTION OF ANDROGEN DEFICIENCY
FIELD OF THE INVENTION
This invention relates to a method for treatment or prevention of androgen deficiency in a male individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator (SERM).
The invention concerns further methods for treatment or prevention of diseases or disorders caused by said androgen deficiency.
BACKGROUND OF THE INVENTION
The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference.
Testosterone in men Masculine sex hormones, the androgens, are responsible for the development of the masculine sex characteristics. Furthermore, they are required for reproduction. The main element of the androgens is testosterone, which is imperative for the development and the function of the internal and external masculine sex organs, which has a supportive influence regarding muscle growth, which determines the distribution and the density of hair growth, which has a positive influence with respect to the production of erythrocytes and with respect to the distribution of erythropoietiin and the cognitive functions. A shortage of testosterone (hypogonadism) may be classified into two principle forms, which are designated primary and secondary hypogonadism. Diseases based on testosterone shortage include for instance osteoporosis, muscle atrophy, senescence outfall symptoms, the decrease of libido and potency, depression and anaemia.
Primary hypogonadism The lack of testosterone production or a decreased testosterone production within the body, originating from a malfunction of the testicles, which is the main synthesis location of testosterone, is designated primary hypogonadism.
Primary hypogonadism includes the testicular failure due to congenital or acquired anorchia, XYY Syndrome, XX males, Noonan's Syndrome, gonadal dysgenesis, Leydig cell tumors, maldescended testes, varicocele, Sertoli-Cell-Only Syndrome, cryptorchidism, bilateral torsion, vanishing testis syndrome, orchiectomy, Klinefelter's Syndrome, chemotherapy, toxic damage from alcohol or heavy metals, and general disease (renal failure, liver cirrhosis, diabetes, myotonia dystrophica).
Patients with primary hypogonadism show an intact feedback mechanism in that the low serum testosterone concentrations are associated with high FSH (follicle-stimulating hormone) and LH (luteinizing hormone) concentrations. However, because of testicular or other failures, the high LH concentrations are not effective at stimulating testosterone production.
Secondary hypogonadism If the main reason for the diseases is a malfunction of the hypothalamus or the hypophysis the disease is named secondary (or hypogonadotrophic) hypogonadism.
This involves an idiopathic gonadotropin or LH-releasing hormone deficiency.
This type of hypogonadism includes Kallman's Syndrome, Prader-Labhart-Willi's Syndrome, Laurence-Moon-Biedl's Syndrome, pituitary insufficiency/adenomas, Pasqualini's Syndrome, hemochromatosis, hyperprolactinemia, or pituitary-hypothalamic injury from tumors, trauma, radiation, or obesity. Because patients with secondary hypogonadism do not demonstrate an intact feedback pathway, the lower testosterone concentrations are not associated with increased LH or FSH
levels. Thus, these men have low testosterone serum levels but have gonadotropins in the normal to low range.
OF A PHARMACEUTICAL PREPARATION FOR USE IN A METHOD FOR THE TREATMENT
OR PREVENTION OF ANDROGEN DEFICIENCY
FIELD OF THE INVENTION
This invention relates to a method for treatment or prevention of androgen deficiency in a male individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator (SERM).
The invention concerns further methods for treatment or prevention of diseases or disorders caused by said androgen deficiency.
BACKGROUND OF THE INVENTION
The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference.
Testosterone in men Masculine sex hormones, the androgens, are responsible for the development of the masculine sex characteristics. Furthermore, they are required for reproduction. The main element of the androgens is testosterone, which is imperative for the development and the function of the internal and external masculine sex organs, which has a supportive influence regarding muscle growth, which determines the distribution and the density of hair growth, which has a positive influence with respect to the production of erythrocytes and with respect to the distribution of erythropoietiin and the cognitive functions. A shortage of testosterone (hypogonadism) may be classified into two principle forms, which are designated primary and secondary hypogonadism. Diseases based on testosterone shortage include for instance osteoporosis, muscle atrophy, senescence outfall symptoms, the decrease of libido and potency, depression and anaemia.
Primary hypogonadism The lack of testosterone production or a decreased testosterone production within the body, originating from a malfunction of the testicles, which is the main synthesis location of testosterone, is designated primary hypogonadism.
Primary hypogonadism includes the testicular failure due to congenital or acquired anorchia, XYY Syndrome, XX males, Noonan's Syndrome, gonadal dysgenesis, Leydig cell tumors, maldescended testes, varicocele, Sertoli-Cell-Only Syndrome, cryptorchidism, bilateral torsion, vanishing testis syndrome, orchiectomy, Klinefelter's Syndrome, chemotherapy, toxic damage from alcohol or heavy metals, and general disease (renal failure, liver cirrhosis, diabetes, myotonia dystrophica).
Patients with primary hypogonadism show an intact feedback mechanism in that the low serum testosterone concentrations are associated with high FSH (follicle-stimulating hormone) and LH (luteinizing hormone) concentrations. However, because of testicular or other failures, the high LH concentrations are not effective at stimulating testosterone production.
Secondary hypogonadism If the main reason for the diseases is a malfunction of the hypothalamus or the hypophysis the disease is named secondary (or hypogonadotrophic) hypogonadism.
This involves an idiopathic gonadotropin or LH-releasing hormone deficiency.
This type of hypogonadism includes Kallman's Syndrome, Prader-Labhart-Willi's Syndrome, Laurence-Moon-Biedl's Syndrome, pituitary insufficiency/adenomas, Pasqualini's Syndrome, hemochromatosis, hyperprolactinemia, or pituitary-hypothalamic injury from tumors, trauma, radiation, or obesity. Because patients with secondary hypogonadism do not demonstrate an intact feedback pathway, the lower testosterone concentrations are not associated with increased LH or FSH
levels. Thus, these men have low testosterone serum levels but have gonadotropins in the normal to low range.
Age-related testosterone deficiency, Men experience a slow but continuous decline in average serum testosterone after approximately age 20 to 30 years. Researchers estimate that the decline is about 1-2% per year. Moreover, as men age, the circadian rhythm of testosterone concentration is often muted, dampened, or completely lost. The untreated testosterone deficiency in older men may lead to a variety of physiological changes, including sexual dysfunction, decreased libido, loss of muscle mass, decreased bone density, depressed mood, and decreased cognitive function. The net result is male andropause, also known as late-onset hypogonadism or androgen decline in the ageing male (ADAM).
Diagnosis and treatment of testosterone deficiency The normal ranges for testosterone concentration vary as well as the definition of the limit value to diagnose hypogonadism. The report of the Endocrine Society's Second Annual Andropause Consensus Meeting (Endocrine Society, 2002) delineated three categories for consideration in screening and diagnosing hypogonadism in men over 50 years of age: 1) if total testosterone is _ 200 ng/dL
(i.e., 7 nmol/L), diagnosis of androgen deficiency is confirmed; serious hypothalamic or pituitary disease in men with hypogonadotropic hypogonadism to be ruled out; 2) if total testosterone levels are between 200 and 400 ng/dL
(i.e., 7-14 nmol/L), additional measures of testosterone and further evaluation before considering testosterone therapy are recommended; and 3) if total testosterone levels are > 400 ng/dL (i.e., 14 nmol/L), there is no testosterone deficiency.
Many studies have used the 300 to 350 ng/dL (i.e., 10-12 nmol/L) range of total testosterone as a cutoff for identifying hypogonadal patients (in Testosterone and Aging, Clinical Research Directions 2004, ed. Liverman CT and Blaxer DG). In addition to the low testosterone serum concentration, sign(s) and/or symptom(s) of testosterone deficiency should be present for the diagnosis.
Diagnosis and treatment of testosterone deficiency The normal ranges for testosterone concentration vary as well as the definition of the limit value to diagnose hypogonadism. The report of the Endocrine Society's Second Annual Andropause Consensus Meeting (Endocrine Society, 2002) delineated three categories for consideration in screening and diagnosing hypogonadism in men over 50 years of age: 1) if total testosterone is _ 200 ng/dL
(i.e., 7 nmol/L), diagnosis of androgen deficiency is confirmed; serious hypothalamic or pituitary disease in men with hypogonadotropic hypogonadism to be ruled out; 2) if total testosterone levels are between 200 and 400 ng/dL
(i.e., 7-14 nmol/L), additional measures of testosterone and further evaluation before considering testosterone therapy are recommended; and 3) if total testosterone levels are > 400 ng/dL (i.e., 14 nmol/L), there is no testosterone deficiency.
Many studies have used the 300 to 350 ng/dL (i.e., 10-12 nmol/L) range of total testosterone as a cutoff for identifying hypogonadal patients (in Testosterone and Aging, Clinical Research Directions 2004, ed. Liverman CT and Blaxer DG). In addition to the low testosterone serum concentration, sign(s) and/or symptom(s) of testosterone deficiency should be present for the diagnosis.
The treatment is usually a substitution therapy which effectively can be measured directly based on the testosterone concentration in serum. The aim of the testosterone substitution is to increase the testosterone concentration in serum to the normal value. Currently, testosterone/androgen compounds are used as treatments for hypogonadism.
Selective estrogen receptor modulators "SERM"s (selective estrogen receptor modulators) have both estrogen-like and antiestrogenic properties (Kauffinan & Bryant, Drug News Perspect 8:531-539, 1995). The effects may be tissue-specific as in the case of tamoxifen and toremifene which have estrogen-like effects in the bone, partial estrogen-like effect in the uterus and liver, and pure antiestrogenic effect in breast cancer. Raloxifene and droloxifen are similar to tamoxifen and toremifene, except that their antiestrogenic properties dominate. They are known to decrease total and LDL cholesterol, thus deminishing the risk of cardiovascular diseases, and they may prevent osteoporosis and inhibit breast cancer growth in postmenopausal women.
A review of investigated and/or marketed SERM compounds is published in V
Craig Jordan, J Medicinal Chemistry (2003):46, No.7.
SUMMARY OF THE INVENTION
The inventors of the present invention have surprisingly found that compounds belonging to the group of selective estrogen receptor modulators are effective in raising the serum testosterone level in men.
Thus, this invention concerns a method for treatment or prevention of of androgen deficiency in a male individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof.
Furthermore, this invention concerns a method for prevention or treatment of a disease or disorder in a male individual, said disease or disorder being caused by androgen deficiency in said individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator as defined 5 in any of the claims 1-6, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof.
BRIEF DESCRIPTION OF THE DRAWING
Figure 1 shows serum concentration of testosterone in men versus time during treatment with different doses of fispemifene.
DETAILED DESCRIPTION OF THE INVENTION
Definitions The tem "treatment" or "treating" shall be understood to include complete curing of a disease or disorder, amelioration or alleviation and of said disease or disorder and delaying the progress or onset of said disease or disorder.
The term "prevention" shall be understood to include complete prevention, prophylaxis, as well as lowering the individual's risk of falling ill with said disease or disorder.
The term "individual" refers to a human or animal subject.
The expression "effective amount" is meant to include any amount of an agent according to the present invention that is sufficient to bring about a desired therapeutical result, especially upon administration to an animal or human subject.
Selective estrogen receptor modulators "SERM"s (selective estrogen receptor modulators) have both estrogen-like and antiestrogenic properties (Kauffinan & Bryant, Drug News Perspect 8:531-539, 1995). The effects may be tissue-specific as in the case of tamoxifen and toremifene which have estrogen-like effects in the bone, partial estrogen-like effect in the uterus and liver, and pure antiestrogenic effect in breast cancer. Raloxifene and droloxifen are similar to tamoxifen and toremifene, except that their antiestrogenic properties dominate. They are known to decrease total and LDL cholesterol, thus deminishing the risk of cardiovascular diseases, and they may prevent osteoporosis and inhibit breast cancer growth in postmenopausal women.
A review of investigated and/or marketed SERM compounds is published in V
Craig Jordan, J Medicinal Chemistry (2003):46, No.7.
SUMMARY OF THE INVENTION
The inventors of the present invention have surprisingly found that compounds belonging to the group of selective estrogen receptor modulators are effective in raising the serum testosterone level in men.
Thus, this invention concerns a method for treatment or prevention of of androgen deficiency in a male individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof.
Furthermore, this invention concerns a method for prevention or treatment of a disease or disorder in a male individual, said disease or disorder being caused by androgen deficiency in said individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator as defined 5 in any of the claims 1-6, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof.
BRIEF DESCRIPTION OF THE DRAWING
Figure 1 shows serum concentration of testosterone in men versus time during treatment with different doses of fispemifene.
DETAILED DESCRIPTION OF THE INVENTION
Definitions The tem "treatment" or "treating" shall be understood to include complete curing of a disease or disorder, amelioration or alleviation and of said disease or disorder and delaying the progress or onset of said disease or disorder.
The term "prevention" shall be understood to include complete prevention, prophylaxis, as well as lowering the individual's risk of falling ill with said disease or disorder.
The term "individual" refers to a human or animal subject.
The expression "effective amount" is meant to include any amount of an agent according to the present invention that is sufficient to bring about a desired therapeutical result, especially upon administration to an animal or human subject.
The term "androgen deficiency" shall mean a condition in the male individual where the serum level of masculine sex honnones, particularly testosterone and dihydrotestosterone, is decreased.
The term "testosterone deficiency" refers to a condition in the male individual where the seruni level of testosterone is decreased, particularly decreased to a serum level below or at the lower range of the normal reference level. The reference level depends on the laboratory methods used.
The wording "selective estrogen receptor modulator" and any specific compound belonging to this group shall be understood to cover any geometric isomer, any stereoisomer, racemate or other mixture of isomers of the compound.
Furthermore, pharmaceutically acceptable salts and other derivatives such as esters as well as metabolites are also included.
Diseases or disorders which can be prevented or treated by treating or preventing androgen deficiency using SERMs The inventors believe that SERMs are useful for prevention or treatment of any disease or disorder in male individual, said disease or disorder being caused by androgen deficiency.
Hypogonadism, particularly secondary hypogonadism, and age-related testosterone deficiency are examples of disorders which can treated or prevented by administrating SERMs according to this invention. Also specific diseases or disorders resulting from said hypogonadism or age-related testosterone deficiency can be treated or prevented. However, also other diseases or disorders which are caused by androgen deficiency but which are unrelated to hypogonadism or age-related testosterone deficiency may be treated or prevented according to the method of this invention.
The term "testosterone deficiency" refers to a condition in the male individual where the seruni level of testosterone is decreased, particularly decreased to a serum level below or at the lower range of the normal reference level. The reference level depends on the laboratory methods used.
The wording "selective estrogen receptor modulator" and any specific compound belonging to this group shall be understood to cover any geometric isomer, any stereoisomer, racemate or other mixture of isomers of the compound.
Furthermore, pharmaceutically acceptable salts and other derivatives such as esters as well as metabolites are also included.
Diseases or disorders which can be prevented or treated by treating or preventing androgen deficiency using SERMs The inventors believe that SERMs are useful for prevention or treatment of any disease or disorder in male individual, said disease or disorder being caused by androgen deficiency.
Hypogonadism, particularly secondary hypogonadism, and age-related testosterone deficiency are examples of disorders which can treated or prevented by administrating SERMs according to this invention. Also specific diseases or disorders resulting from said hypogonadism or age-related testosterone deficiency can be treated or prevented. However, also other diseases or disorders which are caused by androgen deficiency but which are unrelated to hypogonadism or age-related testosterone deficiency may be treated or prevented according to the method of this invention.
Thus, as examples of specific diseases or disorder which can be treated or prevented according to the present invention can be mentioned:
- hypogonadism, particularly but not restricted to secondary hypogonadism resulting from diseases or disorders such as Kallman's Syndrome, Prader-Labhart-Willi's Syndrome, Laurence-Moon-Biedl's Syndrome, pituitary insufficiency/adenomas, Pasqualini's Syndrome, hemochromatosis, hyperprolactinemia, pituitary-hypothalamic injury from tumors, trauma, radiation,, obesity, chronic illness, such as diabetes mellitus, hypotyroidism or other disease or disorder that may affect central production of gonadotropin;
- age-related testosteroize deficiency and diseases or disorders resulting therefrom, such as impaired muscle strength, sexual dysfunction, decreased libido, loss of muscle mass, decreased bone density, depressed mood, and decreased cognitive function; and - any muscular atrophy/dystrophies; lipodistrophy; long-term critical illness;
sarcopenia; frailty or age-related functional decline; reduced muscle strength and function; muscle wasting from HIV; chronic renal failure, reduced bone density or growth; catabolic side effects of glucocorticoids; chronic fatigue syndrome;
reduced bone fracture repair; acute fatigue syndrome and muscle loss followiing elective surgery; cachesia; chronic catabolic state; eating disorders; side effects of chemotherapy; wasting; depression; nervousness irritability; stress; growth retardation; senescence outfall symptoms; reduced cognitive function; anaemia;
male contraception; infertility; Syndrome X; diabetic complications or obesity.
SERMs increasing testosterone have the potential to provide novel treatments for male andropause, also known as late-onset hypogonadism or androgen decline in the aging male (ADAM), and both osteoporosis and sexual dysfunction in both men and women. Testosterone deficiency in older men may impair muscle strength (causing frailty/disability); cognitive or sexual function; or vitality/well-being/quality of life.
Advantages of SERMs in the treatment of androgen deficiency ~
A SERM increasing testosterone sufficiently to treat testosterone deficiency may have several advantages over direct testosterone substitution. The benefits of the increased testosterone can be achieved while a SERM compound, due to its anti-estrogenic or estrogenic effects, simultaneously protects against the potential side-effects commonly associated with increased testosterone such as prostate stimulation, gynecomastia, or adverse effects on lipid metabolism.
It is known that many estrogens/anti-estrogens/phytoestrogens/SERMs have antitumor effects mediated via estrogen receptor, and they can potentially prevent and treat prostate cancer (Ho S-M: Estrogens and Anti-Estrogens: Key Mediators of Prostate Carcinogenesis and New Therapeutic Candidates. 2004;91:491-503).
The SERMs are antiestrogenic in breast and could therefore provide protection against gynecomastia, often associated with testosterone treatments.
The SERMs provide beneficial effects on the lipid profile such as increased HDL, and decreased total cholesterol and LDL. Testosterone is known for instance to decrease HDL, and this adverse effect could thus be counteracted with the SERM.
Both SERMs and testosterone have beneficial effects on bone metabolism by inhibiting bone turnover. Thus, the protective effect of a SERM on bone is likely to be enhanced if it has the ability to increase testosterone.
To sum up, SERMs, particularly the SERMs according to formula (I) presented below, produce the positive response of androgen replacement therapy without the undesired side effects of testosterone, such as adverse effects on prostate or on lipid metabolism, or gynecomastia.
These compounds increase testosterone and thus stimulate muscle growth and reduce subcutaneous and visceral abdominal fat in the treatment of obesity;
increase energy and libido and minimize the bone depletion; and have beneficial effects on lipid metabolism.
Preferable SERMs Suitable selective estrogen receptor modulators (or SERMs) for use in this invention are, for example, the compounds disclosed in V Craig Jordan (2003).
Thus, examples of suitable SERM compounds for use in the present invention are triphenylalkene or triphenylalkane compounds such as compounds disclosed in WO
01/36360, US 4,996,225, US 4,696,949, US 5,750,576, WO 99/42427 and the toremifene metabolites disclosed in L Kangas, Cancer Chemother Pharmacol (1990)27:8-12. As examples of specific drugs disclosed in the aforementioned references can be mentioned toreinifene, fispeinifene and ospemifene.
Droloxifene and iodoxifene also examples of suitable SERMs of triphenylalkene structure.
Other preferable examples of SERM compounds are compounds of benzothiophene structure (described for example in EP 584952, US 4,133,814, US 4,418,068) and arzoxifene.
As further examples of suitable SERMs can be mentioned EM652, EM800, EM776, EM651, EM312, ICI 182780, ERA-923, zindoxifene and deacetylated zindoxifene, ZK119010, TSE-4247, lasoxifene and its analogues, particularly those disclosed in EP 802910, nafoxidine, basedoxifene, GW5638, GW7604, compound no. 32 disclosed in Jordan (2003), ICI 164384, RU 58668, RU 39411 and EM 319.
Preferably, the SERM is a triphenylalkane compound, a triphenyl-alkene compound, where the alkene chain is halogen-substituted butene or propene, a benzothiophene compound, EM652, EM800, EM776, EM651, EM312, ICI 182780, ERA-923, zindoxifene, deacetylated zindoxifene, ZK1 19010, TSE-4247, lasoxifene, a lasoxifene analogue, nafoxidine, basedoxifene, GW5638, GW7604, ICI 164384, RU 58668, RU 39411 or EM 319, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof.
Still more preferably, the SERM is a triphenylbutene compound of the formula (I) R1 \ \ \ ~l) CI
wherein R1 is H, halogen, OCH3, or OH; and R2 is a) ~ R4 -X-(CH2)-- CH2 N
5 where X is 0, NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, -CH2C=CH or -CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or 10 b) -Y-(CH2)r,CH2-O-R6 where Y is 0, NH or S and n is an integer from 1 to 4; and R6 is H, -CH2CH2OH, or -CHaCH2C1; or c) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and R3 is H, halogen, OH or -OCH3 or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof.
Still more preferably, the SERM is a triphenylbutene compound of the formula (I) Ri \ \ \ I (I) ci wherein R1 is H, halogen, OCH3, or OH; and R2 is a) ~ R4 -X-(CH2)F-CH2-N
where i) X is NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, -CH2C=CH or -CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or where ii) X is 0, and n is an integer from 1 to 4; and one of R4 and R5 is -CH2C=CH or -CHZCH2OH and the other is H or a C 1-C4-alkyl; or R4 and R5 form an imidazole ring, an N-containing six-membered ring or heteroaromatic ring; or R2 is b) -Y-(CH2)õCH2-O-R6 where Y is 0, NH or S and n is an integer from 1 to 4; and R6 is H, -CH2CHZOH, or -CH2CH2C1; or R2 is c) 2,3-dihydroxypropoxy, 2-methylthioethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and R3 is H, halogen, OH or -OCH3 or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof.
The aforementioned specific SERMs or classes of SERMs are examples only, and other SERMs may be suitable for use in this invention as well.
Preferable SERMs are compounds with tissue specific antiestrogenic or estrogenic effects suitable for men. A preferred SERM is estrogenic in bone and antiestrogenic or mildly estrogenic in other tissues. A classical method to determine the estrogenic profile of a compound is to evaluate estrogenic effect in immature mouse or rat uterus (Terenius L, Acta Endocrinol 66:431-447, 1971). The animals are exposed for 3 days to the compounds to be investigated at the age of 18 days. On the fourth day the animals are sacrificed and body weight and uterine weight is recorded.
Estrogens increase the size and weight of the uterus (uterotropic effect) while antiestrogens inhibit this action. The results are given as per cent of estrogen stimulation (100 % with estradiol). In our tests, we used a high dose level, i.e. 10-50 mg/kg. Compounds causing an uterotropic effect < 40 % are for this purpose classified as weak estrogenic compounds, compounds causing an uterotropic effect > 70 % are classified as strong estrogenic compounds and compounds in-between, an uterotropic effect of 41-69 % are classified as moderate estrogenic agents.
As specific examples of particularly useful SERMs can be mentioned certain compounds of those disclosed in WO 01/36360, namely (Z)-2-[3-(4-Chloro-1,2-diphenyl-but-l-enyl)phenoxy]ethanol (Z)-2-{2-[4-(4-Chloro-1,2-diphenylbut-l-enyl)phenoxy]ethoxy}ethanol (also known under the generic name fispemifene) (Z)- {2-[3-(4-Chloro-1,2-diphenylbut-l-enyl)phenoxy]ethyl} dimethylamine (E)-3 - {4-Chloro-1-[4-(2-hydroxyethoxy)phenyl]-2-phenyl-but-1-enyl}-phenol (E)-3- {4-Chloro-l-[4-(2-imidazol-l-yl-ethoxy)phenyl]-2-phenyl-but-l-enyl}-phenol, (Z)-3 - {4-Chloro-l- [4-(2-iinidazol-1-yl-ethoxy)phenyl] -2-phenyl-but-l-enyl } -phenol, and (Z)- 2-[4-(4-Chloro-1,2-diphenyl-but-l-enyl)phenoxy]ethanol (ospemifene) The aforementioned seven compounds are all classified as weak estrogenic SERMs.
For the purpose of this invention, the SERM or its isomer, isomer mixture or their pharmaceutically acceptable salts can be administered by various routes. The suitable administration forms include, for example, oral formulations;
parenteral injections including intravenous, intramuscular, intradermal and subcutanous injections; and transdermal or rectal formulations. Suitable oral formulations include e.g. conventional or slow-release tablets and gelatine capsules.
The required dosage of the SERM compounds will vary with the particular condition being treated, the severity of the condition, the duration of the treatment, the administration route and the specific compound being employed. For example, fispemifene can be administered perorally preferentially once daily. The daily dose may be 5 -1500 mg, preferably 20-1500 mg. Fispemifene can be given as tablets or other formulations like gelatine capsules alone or mixed in any clinically acceptable non-active ingredients which are used in the pharmaceutical industry.
The invention will be illuminated by the following non-restrictive Experimental Section.
EXPERIMENTAL SECTION
Methods and materials Fispemifene has been studied in two phase I studies in humans - in a single dose and a repeated dose study. Effect of fispemifene on hormone levels was one main focus of the repeated dose study. The phase I repeated dose study (number 101-50202) was a randomized, double-blind, placebo-controlled 28-day dose-escalation study performed in 32 healthy, elderly men, aged 50-68 years. The main objective of the study was to investigate the tolerability, safety and phaimacokinetics of fispemifene after repeated oral doses, but the study focused also on the effects of fispemifene on serum testosterone, estradiol, and other relevant hormones. The fispemifene doses 10, 30, 100 and 300 mg per day and placebo were administered once every morning as capsules containing 10 mg or 100 mg of fispemifene, or placebo. The dose was escalated to the next higher dose level, if the previous dose had been safe and well tolerated evaluated by the laboratory safety determinations and ultrasound of mammagy glands.
The variables for safety and tolerability were adverse events, vital signs, 12-lead ECG, clinical laboratory evaluations, physical examination, ultrasound examinations (mammary glands) and inhibin b. For pharmacokinetics, the concentrations of fispemifene and its metabolite(s) were to be evaluated. For pharmacodynamics, serum concentrations of FSH, LH, estradiol, testosterone, SHBG, prolactin, aldosterone, cortisol and TSH before and during treatment were measured and compared with the concentrations in the placebo-group.
Results on the effects of fispemifene on hormones Surprisingly, fispemifene increased the serum concentrations of testosterone, FSH, LH, and SHBG (Table 1) during the 28 days of treatment. Testosterone was increased statistically significantly with 100 mg and 300 mg fispemifene compared with placebo. With the 300 mg dose, the increase in the mean total testosterone was about 75% compared to the baseline concentration. Two out of six men treated with the highest fispemifene dose had their serum testosterone level above the upper limit of normal range (i.e., 33 nmol/L) during treatment. The rest two had a significant increase within the reference range. All the six men had normal testosterone value at baseline. With the 100 mg dose, the increase of the mean total testosterone was about 32%, and all the six men in the group had their testosterone level increased within the reference range. The increase in total testosterone levels in serum is illustrated by group in Figure 1. There were no safety concerns raised with any dose suggesting that even a higher dose could be utilized if deemed appropriate.
Table 1. Serum total testosterone concentrations (mean and SD) and the other hormones at baseline and during treatment in the fispemifene study 101-50202 by dose.
Placebo Fispemifene Fispemifene Fispemifene Fispemifene 10 mg 30 mg 100 mg 300 mg Testosterone Mean SD Mean SD Mean SD Mean SD Mean SD
(nmolli) Baseline 17.25 4.2 19.33 4.7 15.00 3.5 14.27 4.0 15.67 3.6 Day 8 18.50 4.1 19.83 3.3 14.40 2.1 18.67 5.3 23.17 5.2 Day 15 18.43 4.4 20.50 4.9 15.00 2.7 19.00 6.0 27.00 6.5 Day 22 17.50 8.5 22.00 4.4 15.80 3.9 17.83 4.5 27.83 4.7 Day 28 15.43 3.2 17.40 7.2 14.80 5.3 18.83 4.8 27.50 10.3 FSH (U/I) Baseline 5.60 3.4 5.42 3.6 9.14 13.4 6.30 5.6 6.80 5.4 Day 8 5.65 2.9 5.87 4.2 9.78 14.2 7.68 7.8 8.80 7.6 Day 15 4.67 1.6 5.20 2.9 10.14 14.6 8.10 9.0 8.73 7.2 Day 22 4.47 1.6 6.60 4.1 10.18 15.1 8.20 9.0 8.85 8.1 Day 28 4.29 1.7 5.66 3.7 8.42 11.6 7.73 7.9 7.57 7.0 LH (Ull) Baseline 3.11 1.6 3.47 1.0 3.58 2.0 4.12 1.9 4.58 2.7 Day 8 3.29 0.8 3.12 1.5 4.26 2.2 5.52 4.2 . 6.80 3.5 Day 15 3.31 0.9 2.87 1.1 5.02 2.4 6.82 7.5 6.75 4.6 Day 22 2.80 0.8 3.56 1.2 4.32 2.3 7.18 8.3 7.77 6.6 Day 28 2.71 0.9 3.02 0.9 4.42 2.0 7.60 9.6 6.70 4.8 Estradiol (pmolll) Baseline 100.6 31.2 106.2 20.9 97.8 17.9 84.3 22.6 102.5 30.0 Day 8 93.8 17.1 94.7 31.2 105.6 29.8 108.3 28.9 104.0 20.0 Day 15 85.0 31.6 81.7 25.4 102.4 22.2 111.5 48.2 97.8 26.9 Day 22 75.0 32.4 116.6 15.1 99.6 20.4 106.3 37.4 95.5 32.9 Day 28 73.6 32.6 75.0 20.1 87.0 22.2 94.5 48.4 89.7 30.9 SHBG
(nmolll) Baseline 49.1 18.6 47.7 19.9 34.2 12.8 41.7 29.4 50.7 15.1 Day 8 44.5 16.1 46.3 21.1 34.2 12.2 47.7 35.2 64.2 21.3 Day 15 46.0 19.1 48.2 22.8 37.4 20.8 52.0 39.5 66.2 21.1 Day 22 44.9 18.4 50.2 27.1 37.2 19.2 55.7 45.3 65.2 14.8 Day 28 45.0 18.5 45.2 24.3 36.6 19.1 50.8 42.8 58.3 12.3 Discussion and conclusions Fispemifene induced a clinically and statistically significant and dose dependent increase in the serum testosterone concentration within 28 days from the start of the 10 treatment. Also, within the 28-day treatment, the increase in testosterone serum concentration was seen in all the subjects treated with 100 mg or 300 mg fispemifene. An increase of 75% from baseline can be considered clinically highly significant, and thus clinical benefits in men with low testosterone can be expected.
The increases also in LH and FSH suggest that fispemifene has an antiestrogenic 15 effect on hypothalamus/hypophysis, and that the increase in testosterone occurs due to the increase in the hypophyseal hormones. The increase in testosterone is moderate and, therefore, no harmful effects often associated with external testosterone administration are expected. Furthermore, a SERM is likely to provide protection against the possible safety problems of testosterone like development of prostate cancer. Thus, a SERM increasing testosterone provides an optimal treatment for hypogonadism, balancing the efficacy and safety of the increased testosterone.
It will be appreciated that the methods of the present invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent for the expert skilled in the field that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are illustrative and should not be construed as restrictive.
- hypogonadism, particularly but not restricted to secondary hypogonadism resulting from diseases or disorders such as Kallman's Syndrome, Prader-Labhart-Willi's Syndrome, Laurence-Moon-Biedl's Syndrome, pituitary insufficiency/adenomas, Pasqualini's Syndrome, hemochromatosis, hyperprolactinemia, pituitary-hypothalamic injury from tumors, trauma, radiation,, obesity, chronic illness, such as diabetes mellitus, hypotyroidism or other disease or disorder that may affect central production of gonadotropin;
- age-related testosteroize deficiency and diseases or disorders resulting therefrom, such as impaired muscle strength, sexual dysfunction, decreased libido, loss of muscle mass, decreased bone density, depressed mood, and decreased cognitive function; and - any muscular atrophy/dystrophies; lipodistrophy; long-term critical illness;
sarcopenia; frailty or age-related functional decline; reduced muscle strength and function; muscle wasting from HIV; chronic renal failure, reduced bone density or growth; catabolic side effects of glucocorticoids; chronic fatigue syndrome;
reduced bone fracture repair; acute fatigue syndrome and muscle loss followiing elective surgery; cachesia; chronic catabolic state; eating disorders; side effects of chemotherapy; wasting; depression; nervousness irritability; stress; growth retardation; senescence outfall symptoms; reduced cognitive function; anaemia;
male contraception; infertility; Syndrome X; diabetic complications or obesity.
SERMs increasing testosterone have the potential to provide novel treatments for male andropause, also known as late-onset hypogonadism or androgen decline in the aging male (ADAM), and both osteoporosis and sexual dysfunction in both men and women. Testosterone deficiency in older men may impair muscle strength (causing frailty/disability); cognitive or sexual function; or vitality/well-being/quality of life.
Advantages of SERMs in the treatment of androgen deficiency ~
A SERM increasing testosterone sufficiently to treat testosterone deficiency may have several advantages over direct testosterone substitution. The benefits of the increased testosterone can be achieved while a SERM compound, due to its anti-estrogenic or estrogenic effects, simultaneously protects against the potential side-effects commonly associated with increased testosterone such as prostate stimulation, gynecomastia, or adverse effects on lipid metabolism.
It is known that many estrogens/anti-estrogens/phytoestrogens/SERMs have antitumor effects mediated via estrogen receptor, and they can potentially prevent and treat prostate cancer (Ho S-M: Estrogens and Anti-Estrogens: Key Mediators of Prostate Carcinogenesis and New Therapeutic Candidates. 2004;91:491-503).
The SERMs are antiestrogenic in breast and could therefore provide protection against gynecomastia, often associated with testosterone treatments.
The SERMs provide beneficial effects on the lipid profile such as increased HDL, and decreased total cholesterol and LDL. Testosterone is known for instance to decrease HDL, and this adverse effect could thus be counteracted with the SERM.
Both SERMs and testosterone have beneficial effects on bone metabolism by inhibiting bone turnover. Thus, the protective effect of a SERM on bone is likely to be enhanced if it has the ability to increase testosterone.
To sum up, SERMs, particularly the SERMs according to formula (I) presented below, produce the positive response of androgen replacement therapy without the undesired side effects of testosterone, such as adverse effects on prostate or on lipid metabolism, or gynecomastia.
These compounds increase testosterone and thus stimulate muscle growth and reduce subcutaneous and visceral abdominal fat in the treatment of obesity;
increase energy and libido and minimize the bone depletion; and have beneficial effects on lipid metabolism.
Preferable SERMs Suitable selective estrogen receptor modulators (or SERMs) for use in this invention are, for example, the compounds disclosed in V Craig Jordan (2003).
Thus, examples of suitable SERM compounds for use in the present invention are triphenylalkene or triphenylalkane compounds such as compounds disclosed in WO
01/36360, US 4,996,225, US 4,696,949, US 5,750,576, WO 99/42427 and the toremifene metabolites disclosed in L Kangas, Cancer Chemother Pharmacol (1990)27:8-12. As examples of specific drugs disclosed in the aforementioned references can be mentioned toreinifene, fispeinifene and ospemifene.
Droloxifene and iodoxifene also examples of suitable SERMs of triphenylalkene structure.
Other preferable examples of SERM compounds are compounds of benzothiophene structure (described for example in EP 584952, US 4,133,814, US 4,418,068) and arzoxifene.
As further examples of suitable SERMs can be mentioned EM652, EM800, EM776, EM651, EM312, ICI 182780, ERA-923, zindoxifene and deacetylated zindoxifene, ZK119010, TSE-4247, lasoxifene and its analogues, particularly those disclosed in EP 802910, nafoxidine, basedoxifene, GW5638, GW7604, compound no. 32 disclosed in Jordan (2003), ICI 164384, RU 58668, RU 39411 and EM 319.
Preferably, the SERM is a triphenylalkane compound, a triphenyl-alkene compound, where the alkene chain is halogen-substituted butene or propene, a benzothiophene compound, EM652, EM800, EM776, EM651, EM312, ICI 182780, ERA-923, zindoxifene, deacetylated zindoxifene, ZK1 19010, TSE-4247, lasoxifene, a lasoxifene analogue, nafoxidine, basedoxifene, GW5638, GW7604, ICI 164384, RU 58668, RU 39411 or EM 319, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof.
Still more preferably, the SERM is a triphenylbutene compound of the formula (I) R1 \ \ \ ~l) CI
wherein R1 is H, halogen, OCH3, or OH; and R2 is a) ~ R4 -X-(CH2)-- CH2 N
5 where X is 0, NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, -CH2C=CH or -CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or 10 b) -Y-(CH2)r,CH2-O-R6 where Y is 0, NH or S and n is an integer from 1 to 4; and R6 is H, -CH2CH2OH, or -CHaCH2C1; or c) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and R3 is H, halogen, OH or -OCH3 or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof.
Still more preferably, the SERM is a triphenylbutene compound of the formula (I) Ri \ \ \ I (I) ci wherein R1 is H, halogen, OCH3, or OH; and R2 is a) ~ R4 -X-(CH2)F-CH2-N
where i) X is NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, -CH2C=CH or -CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or where ii) X is 0, and n is an integer from 1 to 4; and one of R4 and R5 is -CH2C=CH or -CHZCH2OH and the other is H or a C 1-C4-alkyl; or R4 and R5 form an imidazole ring, an N-containing six-membered ring or heteroaromatic ring; or R2 is b) -Y-(CH2)õCH2-O-R6 where Y is 0, NH or S and n is an integer from 1 to 4; and R6 is H, -CH2CHZOH, or -CH2CH2C1; or R2 is c) 2,3-dihydroxypropoxy, 2-methylthioethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and R3 is H, halogen, OH or -OCH3 or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof.
The aforementioned specific SERMs or classes of SERMs are examples only, and other SERMs may be suitable for use in this invention as well.
Preferable SERMs are compounds with tissue specific antiestrogenic or estrogenic effects suitable for men. A preferred SERM is estrogenic in bone and antiestrogenic or mildly estrogenic in other tissues. A classical method to determine the estrogenic profile of a compound is to evaluate estrogenic effect in immature mouse or rat uterus (Terenius L, Acta Endocrinol 66:431-447, 1971). The animals are exposed for 3 days to the compounds to be investigated at the age of 18 days. On the fourth day the animals are sacrificed and body weight and uterine weight is recorded.
Estrogens increase the size and weight of the uterus (uterotropic effect) while antiestrogens inhibit this action. The results are given as per cent of estrogen stimulation (100 % with estradiol). In our tests, we used a high dose level, i.e. 10-50 mg/kg. Compounds causing an uterotropic effect < 40 % are for this purpose classified as weak estrogenic compounds, compounds causing an uterotropic effect > 70 % are classified as strong estrogenic compounds and compounds in-between, an uterotropic effect of 41-69 % are classified as moderate estrogenic agents.
As specific examples of particularly useful SERMs can be mentioned certain compounds of those disclosed in WO 01/36360, namely (Z)-2-[3-(4-Chloro-1,2-diphenyl-but-l-enyl)phenoxy]ethanol (Z)-2-{2-[4-(4-Chloro-1,2-diphenylbut-l-enyl)phenoxy]ethoxy}ethanol (also known under the generic name fispemifene) (Z)- {2-[3-(4-Chloro-1,2-diphenylbut-l-enyl)phenoxy]ethyl} dimethylamine (E)-3 - {4-Chloro-1-[4-(2-hydroxyethoxy)phenyl]-2-phenyl-but-1-enyl}-phenol (E)-3- {4-Chloro-l-[4-(2-imidazol-l-yl-ethoxy)phenyl]-2-phenyl-but-l-enyl}-phenol, (Z)-3 - {4-Chloro-l- [4-(2-iinidazol-1-yl-ethoxy)phenyl] -2-phenyl-but-l-enyl } -phenol, and (Z)- 2-[4-(4-Chloro-1,2-diphenyl-but-l-enyl)phenoxy]ethanol (ospemifene) The aforementioned seven compounds are all classified as weak estrogenic SERMs.
For the purpose of this invention, the SERM or its isomer, isomer mixture or their pharmaceutically acceptable salts can be administered by various routes. The suitable administration forms include, for example, oral formulations;
parenteral injections including intravenous, intramuscular, intradermal and subcutanous injections; and transdermal or rectal formulations. Suitable oral formulations include e.g. conventional or slow-release tablets and gelatine capsules.
The required dosage of the SERM compounds will vary with the particular condition being treated, the severity of the condition, the duration of the treatment, the administration route and the specific compound being employed. For example, fispemifene can be administered perorally preferentially once daily. The daily dose may be 5 -1500 mg, preferably 20-1500 mg. Fispemifene can be given as tablets or other formulations like gelatine capsules alone or mixed in any clinically acceptable non-active ingredients which are used in the pharmaceutical industry.
The invention will be illuminated by the following non-restrictive Experimental Section.
EXPERIMENTAL SECTION
Methods and materials Fispemifene has been studied in two phase I studies in humans - in a single dose and a repeated dose study. Effect of fispemifene on hormone levels was one main focus of the repeated dose study. The phase I repeated dose study (number 101-50202) was a randomized, double-blind, placebo-controlled 28-day dose-escalation study performed in 32 healthy, elderly men, aged 50-68 years. The main objective of the study was to investigate the tolerability, safety and phaimacokinetics of fispemifene after repeated oral doses, but the study focused also on the effects of fispemifene on serum testosterone, estradiol, and other relevant hormones. The fispemifene doses 10, 30, 100 and 300 mg per day and placebo were administered once every morning as capsules containing 10 mg or 100 mg of fispemifene, or placebo. The dose was escalated to the next higher dose level, if the previous dose had been safe and well tolerated evaluated by the laboratory safety determinations and ultrasound of mammagy glands.
The variables for safety and tolerability were adverse events, vital signs, 12-lead ECG, clinical laboratory evaluations, physical examination, ultrasound examinations (mammary glands) and inhibin b. For pharmacokinetics, the concentrations of fispemifene and its metabolite(s) were to be evaluated. For pharmacodynamics, serum concentrations of FSH, LH, estradiol, testosterone, SHBG, prolactin, aldosterone, cortisol and TSH before and during treatment were measured and compared with the concentrations in the placebo-group.
Results on the effects of fispemifene on hormones Surprisingly, fispemifene increased the serum concentrations of testosterone, FSH, LH, and SHBG (Table 1) during the 28 days of treatment. Testosterone was increased statistically significantly with 100 mg and 300 mg fispemifene compared with placebo. With the 300 mg dose, the increase in the mean total testosterone was about 75% compared to the baseline concentration. Two out of six men treated with the highest fispemifene dose had their serum testosterone level above the upper limit of normal range (i.e., 33 nmol/L) during treatment. The rest two had a significant increase within the reference range. All the six men had normal testosterone value at baseline. With the 100 mg dose, the increase of the mean total testosterone was about 32%, and all the six men in the group had their testosterone level increased within the reference range. The increase in total testosterone levels in serum is illustrated by group in Figure 1. There were no safety concerns raised with any dose suggesting that even a higher dose could be utilized if deemed appropriate.
Table 1. Serum total testosterone concentrations (mean and SD) and the other hormones at baseline and during treatment in the fispemifene study 101-50202 by dose.
Placebo Fispemifene Fispemifene Fispemifene Fispemifene 10 mg 30 mg 100 mg 300 mg Testosterone Mean SD Mean SD Mean SD Mean SD Mean SD
(nmolli) Baseline 17.25 4.2 19.33 4.7 15.00 3.5 14.27 4.0 15.67 3.6 Day 8 18.50 4.1 19.83 3.3 14.40 2.1 18.67 5.3 23.17 5.2 Day 15 18.43 4.4 20.50 4.9 15.00 2.7 19.00 6.0 27.00 6.5 Day 22 17.50 8.5 22.00 4.4 15.80 3.9 17.83 4.5 27.83 4.7 Day 28 15.43 3.2 17.40 7.2 14.80 5.3 18.83 4.8 27.50 10.3 FSH (U/I) Baseline 5.60 3.4 5.42 3.6 9.14 13.4 6.30 5.6 6.80 5.4 Day 8 5.65 2.9 5.87 4.2 9.78 14.2 7.68 7.8 8.80 7.6 Day 15 4.67 1.6 5.20 2.9 10.14 14.6 8.10 9.0 8.73 7.2 Day 22 4.47 1.6 6.60 4.1 10.18 15.1 8.20 9.0 8.85 8.1 Day 28 4.29 1.7 5.66 3.7 8.42 11.6 7.73 7.9 7.57 7.0 LH (Ull) Baseline 3.11 1.6 3.47 1.0 3.58 2.0 4.12 1.9 4.58 2.7 Day 8 3.29 0.8 3.12 1.5 4.26 2.2 5.52 4.2 . 6.80 3.5 Day 15 3.31 0.9 2.87 1.1 5.02 2.4 6.82 7.5 6.75 4.6 Day 22 2.80 0.8 3.56 1.2 4.32 2.3 7.18 8.3 7.77 6.6 Day 28 2.71 0.9 3.02 0.9 4.42 2.0 7.60 9.6 6.70 4.8 Estradiol (pmolll) Baseline 100.6 31.2 106.2 20.9 97.8 17.9 84.3 22.6 102.5 30.0 Day 8 93.8 17.1 94.7 31.2 105.6 29.8 108.3 28.9 104.0 20.0 Day 15 85.0 31.6 81.7 25.4 102.4 22.2 111.5 48.2 97.8 26.9 Day 22 75.0 32.4 116.6 15.1 99.6 20.4 106.3 37.4 95.5 32.9 Day 28 73.6 32.6 75.0 20.1 87.0 22.2 94.5 48.4 89.7 30.9 SHBG
(nmolll) Baseline 49.1 18.6 47.7 19.9 34.2 12.8 41.7 29.4 50.7 15.1 Day 8 44.5 16.1 46.3 21.1 34.2 12.2 47.7 35.2 64.2 21.3 Day 15 46.0 19.1 48.2 22.8 37.4 20.8 52.0 39.5 66.2 21.1 Day 22 44.9 18.4 50.2 27.1 37.2 19.2 55.7 45.3 65.2 14.8 Day 28 45.0 18.5 45.2 24.3 36.6 19.1 50.8 42.8 58.3 12.3 Discussion and conclusions Fispemifene induced a clinically and statistically significant and dose dependent increase in the serum testosterone concentration within 28 days from the start of the 10 treatment. Also, within the 28-day treatment, the increase in testosterone serum concentration was seen in all the subjects treated with 100 mg or 300 mg fispemifene. An increase of 75% from baseline can be considered clinically highly significant, and thus clinical benefits in men with low testosterone can be expected.
The increases also in LH and FSH suggest that fispemifene has an antiestrogenic 15 effect on hypothalamus/hypophysis, and that the increase in testosterone occurs due to the increase in the hypophyseal hormones. The increase in testosterone is moderate and, therefore, no harmful effects often associated with external testosterone administration are expected. Furthermore, a SERM is likely to provide protection against the possible safety problems of testosterone like development of prostate cancer. Thus, a SERM increasing testosterone provides an optimal treatment for hypogonadism, balancing the efficacy and safety of the increased testosterone.
It will be appreciated that the methods of the present invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent for the expert skilled in the field that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are illustrative and should not be construed as restrictive.
Claims (13)
1. The use of a selective estrogen receptor modulator, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency in a male individual.
2. The use according to claim 1 wherein the selective estrogen receptor modulator is a triphenylalkane compound, a triphenyl-alkene compound, where the alkene chain is halogen-substituted butene or propene, a benzothiophene compound, EM652, EM800, EM776, EM651, EM312, ICI 182780, ERA-923, zindoxifene, deacetylated zindoxifene, ZK119010, TSE-4247, lasoxifene, a lasoxifene analogue, nafoxidine, basedoxifene, GW5638, GW7604, ICI 164384, RU 58668, RU 39411 or EM 319, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof.
3. The use according to claim 2 wherein the selective estrogen receptor modulator is a triphenylbutene compound of the formula (I) wherein R1 is H, halogen, OCH3, or OH; and R2 is a) where X is O, NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, -CH2C.ident.CH or -CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or b) -Y-(CH2)n CH2-O-R6 where Y is O, NH or S and n is an integer from 1 to 4; and R6 is H, -CH2CH2OH, or -CH2CH2C1; or c) 2,3-dihydroxypropoxy, 2-methylthioethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and R3 is H, halogen, OH or -OCH3 or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof.
4. The use according to claim 2 wherein the selective estrogen receptor modulator is a triphenylbutene compound of the formula (I) wherein R1 is H, halogen, OCH3, or OH; and R2 is a) where i) X is NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, -CH2C.ident.CH or -CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or where ii) X is O, and n is an integer from 1 to 4; and one of R4 and R5 is -CH2C.ident.CH or -CH2CH2OH and the other is H or a C1-C4-alkyl; or R4 and R5 form an imidazole ring, an N-containing six-membered ring or heteroaromatic ring; or R2 is b) -Y-(CH2)n CH2-O-R6 where Y is O, NH or S and n is an integer from 1 to 4; and R6 is H, -CH2CH2OH, or -CH2CH2C1; or R2 is c) 2,3-dihydroxypropoxy, 2-methylthioethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and R3 is H, halogen, OH or -OCH3 or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof.
5. The use according to any of the foregoing claims wherein the selective estrogen receptor modulator is a compound with tissue specific antiestrogenic or estrogenic effects suitable for men.
6. The use according to claim 5 wherein the selective estrogen receptor modulator is selected from the group consisting of (Z)-2- [3 -(4-Chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol, (Z)-2- {2-[4-(4-Chloro-1,2-diphenylbut-1-enyl)phenoxy]ethoxy} ethanol (fispemifene), (Z)- {2-[3-(4-Chloro-1,2-diphenylbut-1-enyl)phenoxy]ethyl} dimethylamine, (E)-3-{4-Chloro-1-[4-(2-hydroxyethoxy)phenyl]-2-phenyl-but-1-enyl}-phenol, (E)-3-{4-Chloro-1-[4-(2-imidazol-1-yl-ethoxy)phenyl]-2-phenyl-but-1-enyl}-phenol, (Z)-3-{4-Chloro-1-[4-(2-imidazol-1-yl-ethoxy)phenyl]-2-phenyl-but-1-enyl}-phenol, and (Z)-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol (ospemifene), or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof.
7. The use according to claim 6 wherein the selective estrogen receptor modulator is fispemifene or metabolite or a pharmaceutically acceptable salt thereof.
8. A use of a selective estrogen receptor modulator as defined in any of the claims 1-7, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical preparation useful for prevention or treatment of a disease or disorder in a male individual, said disease or disorder being caused by androgen deficiency in said individual.
9. The use according to claim 8, wherein said disease or disorder is selected from the group consisting of - hypogonadism, particularly but not restricted to secondary hypogonadism resulting from disease or disorders such as Kallman's Syndrome, Prader-Labhart-Willi's Syndrome, Laurence-Moon-Biedl's Syndrome, pituitary insufficiency/adenomas, Pasqualini's Syndrome, hemochromatosis, hyperprolactinemia, pituitary-hypothalamic injury from tumors, trauma, radiation, obesity, chronic illness, such as diabetes mellitus, hypotyroidism or other disease or disorder that may affect central production of gonadotropin;
- age-related testosterone deficiency and diseases or disorders resulting therefrom, such as impaired muscle strength, sexual dysfunction, decreased libido, loss of muscle mass, decreased bone density, depressed mood, and decreased cognitive function; and - any muscular atrophy/dystrophies; lipodistrophy; long-term critical illness;
sarcopenia; frailty or age-related functional decline; reduced muscle strength and function; muscle wasting from HIV; chronic renal failure, reduced bone density or growth; catabolic side effects of glucocorticoids; chronic fatigue syndrome;
reduced bone fracture repair; acute fatigue syndrome and muscle loss following elective surgery; cachesia; chronic catabolic state; eating disorders; side effects of chemotherapy; wasting; depression; nervousness irritability; stress; growth retardation; senescence outfall symptoms; reduced cognitive function; anaemia;
male contraception; infertility; Syndrome X; diabetic complications or obesity.
- age-related testosterone deficiency and diseases or disorders resulting therefrom, such as impaired muscle strength, sexual dysfunction, decreased libido, loss of muscle mass, decreased bone density, depressed mood, and decreased cognitive function; and - any muscular atrophy/dystrophies; lipodistrophy; long-term critical illness;
sarcopenia; frailty or age-related functional decline; reduced muscle strength and function; muscle wasting from HIV; chronic renal failure, reduced bone density or growth; catabolic side effects of glucocorticoids; chronic fatigue syndrome;
reduced bone fracture repair; acute fatigue syndrome and muscle loss following elective surgery; cachesia; chronic catabolic state; eating disorders; side effects of chemotherapy; wasting; depression; nervousness irritability; stress; growth retardation; senescence outfall symptoms; reduced cognitive function; anaemia;
male contraception; infertility; Syndrome X; diabetic complications or obesity.
10. The use according to claim 9 wherein said disease or disorder is selected from the group consisting of hypogonadism, particularly but not restricted to secondary hypogonadism and diseases or disorders resulting therefrom and age-related testosterone deficiency and diseases or disorders resulting therefrom, and said selective estrogen receptor modulator is a triphenylbutene compound of the formula (I) wherein R1 is H, halogen, OCH3, or OH; and R2 is a) where X is O, NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, -CH2C.ident.CH or -CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or b) -Y-(CH2)n CH2-O-R6 where Y is O, NH or S and n is an integer from 1 to 4; and R6 is H, -CH2CH2OH, or -CH2CH2Cl; or c) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and R3 is H, halogen, OH or -OCH3 or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof.
11. The use according to claim 10 wherein said selective estrogen receptor modulator is a triphenylbutene compound of the formula (I) wherein R1 is H, halogen, OCH3, or OH; and R2 is a) where i) X is NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, -CH2C.ident.CH or -CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or where ii) X is O, and n is an integer from 1 to 4; and one of R4 and R5 is -CH2C.ident.CH or -CH2CH2OH and the other is H or a C1-C4-alkyl; or R4 and R5 form an imidazole ring, an N-containing six-membered ring or heteroaromatic ring; or R2 is b) -Y-(CH2)n CH2-O-R6 where Y is O, NH or S and n is an integer from 1 to 4; and R6 is H, -CH2CH2OH, or -CH2CH2Cl; or R2 is c) 2,3-dihydroxypropoxy, 2-methylthioethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and R3 is H, halogen, OH or -OCH3 or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof.
12. The use according to claim 11 wherein the selective estrogen receptor modulator is selected from the group consisting of (Z)-2-[3 -(4-Chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol, (Z)-2-{2-[4-(4-Chloro-1,2-diphenylbut-1-enyl)phenoxy]ethoxy}ethanol (fispemifene), (Z)-{2-[3-(4-Chloro-1,2-diphenylbut-1-enyl)phenoxy]ethyl}dimethylamine, (E)-3-{4-Chloro-1-[4-(2-hydroxyethoxy)phenyl]-2-phenyl-but-1-enyl}-phenol, (E)-3-{4-Chloro-1-[4-(2-imidazol-1-yl-ethoxy)phenyl]-2-phenyl-but-1-enyl}-phenol, (Z)-3-{4-Chloro-1-[4-(2-imidazol-1-yl-ethoxy)phenyl]-2-phenyl-but-1-enyl}-phenol, and (Z)-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol (ospemifene), or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof.
13. The use according to claim 12 wherein the selective estrogen receptor modulator is fispemifene or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60690704P | 2004-09-03 | 2004-09-03 | |
| US60/606,907 | 2004-09-03 | ||
| FI20041216A FI20041216A0 (en) | 2004-09-21 | 2004-09-21 | A method of treating or preventing an androgen deficiency |
| FI20041216 | 2004-09-21 | ||
| PCT/FI2005/000333 WO2006024689A1 (en) | 2004-09-03 | 2005-07-20 | Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2578852A1 true CA2578852A1 (en) | 2006-03-09 |
Family
ID=35999733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002578852A Abandoned CA2578852A1 (en) | 2004-09-03 | 2005-07-20 | Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1786408A4 (en) |
| JP (1) | JP2008511615A (en) |
| KR (1) | KR20070059110A (en) |
| AU (1) | AU2005279178A1 (en) |
| BR (1) | BRPI0514701A (en) |
| CA (1) | CA2578852A1 (en) |
| MX (1) | MX2007002606A (en) |
| NO (1) | NO20071160L (en) |
| RU (1) | RU2007112114A (en) |
| WO (1) | WO2006024689A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2590262T3 (en) | 2007-02-14 | 2016-11-21 | Hormos Medical Ltd. | Method for the preparation of triphenylbutene derivatives with therapeutic value |
| WO2008157335A2 (en) * | 2007-06-13 | 2008-12-24 | Quatrx Pharmaceuticals Company | Methods for the treatment of erectile dysfunction using fispemifene |
| MX2012014431A (en) | 2010-06-10 | 2013-02-26 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof. |
| WO2013090829A1 (en) | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| US9744177B2 (en) | 2014-03-10 | 2017-08-29 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
| ES2717546T3 (en) | 2014-12-29 | 2019-06-21 | Olon Spa | Process for the preparation of ospemifene and fispemifene |
| WO2023175010A1 (en) * | 2022-03-15 | 2023-09-21 | Centre D'etude Des Cellules Souches (Cecs) | Use of bazedoxifene for increasing muscle survival |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL120262A (en) * | 1996-02-28 | 2001-01-28 | Pfizer | Droloxifene and derivatives thereof for use in increasing serum testosterone levels |
| US6632447B1 (en) * | 1998-05-07 | 2003-10-14 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| TW593256B (en) * | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| CO5271697A1 (en) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF AFFECTIONS THAT RESPOND TO AN INCREASE OF TESTOSTERONE |
| WO2001091744A1 (en) * | 2000-05-26 | 2001-12-06 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
| US7067557B2 (en) * | 2000-05-26 | 2006-06-27 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
| JP2005515988A (en) * | 2001-11-29 | 2005-06-02 | ジーティーエックス・インコーポレイテッド | Prevention and treatment of androgen deficiency causing osteoporosis |
-
2005
- 2005-07-20 RU RU2007112114/15A patent/RU2007112114A/en not_active Application Discontinuation
- 2005-07-20 EP EP05771627A patent/EP1786408A4/en not_active Withdrawn
- 2005-07-20 BR BRPI0514701-8A patent/BRPI0514701A/en not_active IP Right Cessation
- 2005-07-20 MX MX2007002606A patent/MX2007002606A/en unknown
- 2005-07-20 CA CA002578852A patent/CA2578852A1/en not_active Abandoned
- 2005-07-20 AU AU2005279178A patent/AU2005279178A1/en not_active Abandoned
- 2005-07-20 KR KR1020077006922A patent/KR20070059110A/en not_active Application Discontinuation
- 2005-07-20 WO PCT/FI2005/000333 patent/WO2006024689A1/en active Application Filing
- 2005-07-20 JP JP2007529372A patent/JP2008511615A/en not_active Abandoned
-
2007
- 2007-03-01 NO NO20071160A patent/NO20071160L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2007112114A (en) | 2008-10-10 |
| NO20071160L (en) | 2007-05-25 |
| WO2006024689A1 (en) | 2006-03-09 |
| BRPI0514701A (en) | 2008-06-24 |
| AU2005279178A1 (en) | 2006-03-09 |
| EP1786408A1 (en) | 2007-05-23 |
| JP2008511615A (en) | 2008-04-17 |
| MX2007002606A (en) | 2007-05-15 |
| EP1786408A4 (en) | 2010-07-28 |
| KR20070059110A (en) | 2007-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Smith et al. | Opioid-induced androgen deficiency (OPIAD) | |
| Davis et al. | Clinical review 82: androgens and the postmenopausal woman | |
| AU2013225869B2 (en) | Combination therapy for treating androgen deficiency | |
| US20060293294A1 (en) | Method for treatment or prevention of androgen deficiency | |
| CA2578852A1 (en) | Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency | |
| JP7080117B2 (en) | Treatment of male androgen deficiency symptoms or diseases with the combination of sex steroid precursors and SERMs | |
| KR101403893B1 (en) | New uses for 4,17β-dihydroxyandrost-4-ene-3-one | |
| CN1732007A (en) | Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy | |
| JP2014088442A (en) | Treatment of alzheimer's disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators | |
| JP2015508825A5 (en) | ||
| Clarke et al. | New selective estrogen and androgen receptor modulators | |
| JP6025301B2 (en) | C-19 steroids for therapeutic use | |
| Giannini et al. | Menopause, hormone replacement therapy (HRT) and obesity | |
| JP2015506988A (en) | Selective estrogen receptor modulators with short half-life and uses thereof | |
| CN1893955A (en) | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases | |
| Suárez et al. | Dehydroepiandrosterone treatment attenuates oestrogen-induced pituitary hyperplasia | |
| WO2017059726A1 (en) | Use of capric acid triglyceride compound in the preparation of drugs for treating polycystic ovary syndrome | |
| Khorram | Potential therapeutic effects of prescribed and over-the-counter androgens in women | |
| US20050059646A1 (en) | Use of 4-androstene-3,6,17-trione to elevate testosterone levels and the testosterone/estrogen ratio in males | |
| US20190054044A1 (en) | Oral dosage form of both clomiphene isomers and method of using same to treat secondary hypogonadism and minimize drug side effects in men | |
| FARER | Balancing Hormones in Men over 40 with Anastro Pro™ and DIM Pro2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |